Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 496

1.

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ.

Mod Pathol. 2012 Mar;25(3):471-9. doi: 10.1038/modpathol.2011.176. Epub 2011 Nov 11.

2.

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A.

Am J Pathol. 2014 Mar;184(3):609-17. doi: 10.1016/j.ajpath.2013.11.007. Epub 2013 Dec 28.

PMID:
24378408
3.

Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.

Tsourlakis MC, Schoop M, Plass C, Huland H, Graefen M, Steuber T, Schlomm T, Simon R, Sauter G, Sirma H, Minner S.

Hum Pathol. 2013 Sep;44(9):1789-96. doi: 10.1016/j.humpath.2013.01.022. Epub 2013 May 2.

PMID:
23642739
4.

Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.

Kim SH, Kim SH, Joung JY, Lee GK, Hong EK, Kang KM, Yu A, Nam BH, Chung J, Seo HK, Park WS, Lee KH.

PLoS One. 2015 Apr 21;10(4):e0122498. doi: 10.1371/journal.pone.0122498. eCollection 2015.

5.

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T.

Clin Cancer Res. 2011 Sep 15;17(18):5878-88. doi: 10.1158/1078-0432.CCR-11-1251. Epub 2011 Jul 26.

6.
7.

Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.

Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y.

Cancer. 2015 May 1;121(9):1422-30. doi: 10.1002/cncr.29233. Epub 2015 Jan 13.

8.
9.

ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.

Huang KC, Dolph M, Donnelly B, Bismar TA.

Clin Transl Oncol. 2014 Nov;16(11):973-9. doi: 10.1007/s12094-014-1182-x. Epub 2014 May 6.

PMID:
24796295
10.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

11.

Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.

Kimura T, Furusato B, Miki J, Yamamoto T, Hayashi N, Takahashi H, Kamata Y, van Leenders GJ, Visakorpi T, Egawa S.

Pathol Int. 2012 Nov;62(11):742-8. doi: 10.1111/pin.12006.

PMID:
23121605
12.

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.

Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.

Anticancer Res. 2016 Sep;36(9):4787-93.

PMID:
27630329
13.

A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.

Lippolis G, Edsjö A, Stenman UH, Bjartell A.

Prostate Cancer Prostatic Dis. 2013 Jun;16(2):145-50. doi: 10.1038/pcan.2013.7. Epub 2013 Mar 5.

14.

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Eur J Cancer. 2014 Mar;50(4):852-61. doi: 10.1016/j.ejca.2013.12.003. Epub 2013 Dec 28.

PMID:
24380696
15.

High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Grupp K, Habermann M, Sirma H, Simon R, Steurer S, Hube-Magg C, Prien K, Burkhardt L, Jedrzejewska K, Salomon G, Heinzer H, Wilczak W, Kluth M, Izbicki JR, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Mod Pathol. 2014 Jan;27(1):96-106. doi: 10.1038/modpathol.2013.127. Epub 2013 Jul 26.

16.

Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.

Brooks JD, Wei W, Hawley S, Auman H, Newcomb L, Boyer H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, McKenney JK.

PLoS One. 2015 Jul 14;10(7):e0132343. doi: 10.1371/journal.pone.0132343. eCollection 2015.

17.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
19.

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509. doi: 10.1158/1055-9965.EPI-12-0042. Epub 2012 Jun 26.

20.

Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.

Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H.

Eur Urol. 1999;36(1):21-30.

PMID:
10364651

Supplemental Content

Support Center